Skip to main content
. Author manuscript; available in PMC: 2006 May 9.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1482–1494. doi: 10.1016/j.ijrobp.2005.11.045

Fig. 1.

Fig. 1

Ad/TRAIL-F/RGD is more effective than Ad/gTRAIL in human esophageal adenocarcinoma cell lines. A, Seg-1 cells treated with Ad/TRAIL-F/RGD, Ad/gTRAIL, and Ad/CMV-GFP at an MOI of 1,000 VP for 5 days. Cells treated with PBS were used as a control. There was a strong apoptotic effect of Ad/TRAIL-F/RGD compared with Ad/gTRAIL or Ad/CMV-GFP by cell density and morphology. B, Cell viability determined by the XTT assay in Seg-1 cells 5 days after cells were treated with various vectors at MOI of 1,000 VP. Cells treated with PBS were used as the control, with their viability set at 1. Each experiment was performed in quadruplicate and repeated at least twice. Values are means of quadruplicate assay results. Bars, standard deviation. C, Flow cytometric analysis of apoptosis (sub-G1) in Seg-1 cells at third day after various vector treatment at the indicated MOIs. D, TRAIL expression and activation of the apoptotic signal transduction pathway in Seg-1 3 days after various vector treatments at 500 MOIs using western blot analysis. P<0.05 in Figure 1B and 1C as comparison between Ad/TRAIL-F/RGD and PBS, Ad/gTRAIL, Ad/CMV-GFP respectively and combined.